Drugs.com Clinical Trial ResultsOriginal article
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Data ReadoutpositiveUbamatamabPositive
AI Analysis
Summary
Regeneron announced initial positive results for ubamatamab (MUC16xCD3) showing a high rate of durable responses in patients with advanced low-grade serous ovarian cancer. The data represent early clinical evidence for this investigational bispecific antibody candidate.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
High rate of durable responses in initial study of patients with advanced low-grade serous ovarian cancer
Importance:7/10
Sentiment:
0.75
ovarian cancerimmunotherapybispecific antibodyclinical trialoncology
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 1, 2026 9:10 PM